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The expression of protein A (spa) is repressed by global regulatory loci sarA and agr. Although SarA may
directly bind to the spa promoter to downregulate spa expression, the mechanism by which agr represses spa
expression is not clearly understood. In searching for SarA homologs in the partially released genome, we
found a SarA homolog, encoding a 250-amino-acid protein designated SarS, upstream of the spa gene. The
expression of sarS was almost undetectable in parental strain RN6390 but was highly expressed in agr and sarA
mutants, strains normally expressing high level of protein A. Interestingly, protein A expression was decreased
in a sarS mutant as detected in an immunoblot but returned to near-parental levels in a complemented sarS
mutant. Transcriptional fusion studies with a 158- and a 491-bp spa promoter fragment linked to the xylE
reporter gene disclosed that the transcription of the spa promoter was also downregulated in the sarS mutant
compared with the parental strain. Interestingly, the enhancement in spa expression in an agr mutant returned
to a near-parental level in the agr sarS double mutant but not in the sarA sarS double mutant. Correlating with
this divergent finding is the observation that enhanced sarS expression in an agr mutant was repressed by the
sarA locus supplied in trans but not in a sarA mutant expressing RNAIII from a plasmid. Gel shift studies also
revealed the specific binding of SarS to the 158-bp spa promoter. Taken together, these data indicated that the
agr locus probably mediates spa repression by suppressing the transcription of sarS, an activator of spa
expression. However, the pathway by which the sarA locus downregulates spa expression is sarS independent.
will activate the transcription of RNAIII, the agr regulatory
molecule, to modulate target gene transcription (15, 23, 26).
In contrast to agr, the sarA locus upregulates the synthesis of
selected extracellular (e.g., ␣ and ␤ hemolysins) and cell wall
proteins (e.g., fibronectin-binding protein A). Like the agr locus, the sarA locus also represses the transcription of the protein A gene (spa) (7). The sarA locus, contained within a 1.2-kb
fragment, is composed of three overlapping transcripts, all
encoding the major 372-bp sarA gene (1). DNA-binding studies revealed that SarA, the major sarA regulatory molecule,
binds to several target gene promoters, including those of agr,
hla (␣ hemolysin gene), and spa. Accordingly, the binding of
SarA to a conserved binding site present in many target gene
promoters leads to an upregulation in agr and hla transcription,
as well as to a downregulation in spa transcription, thus implicating SarA to be a regulatory molecule that modulates target
genes via both agr-dependent and agr-independent pathways
(9).
Considering the fact that both sarA and agr repress spa
transcription, it seems reasonable to predict the existence of
regulatory element(s) that counteracts this mode of regulation
(i.e., activating spa). In searching for SarA homolog(s) in the
S. aureus genome (The Institute for Genome Research [TIGR]),
we came upon an open reading frame (ORF) upstream of the
spa gene that shares homology with SarA. Transcriptional
analysis indicated that the expression of this gene, designated
sarS for a gene supplemental to SarA, is enhanced in sarA and
agr mutants, while the transcription of sarA and agr loci is
unaltered in a sarS mutant. Inactivation of this gene leads to a
decrease in protein A expression on immunoblots. Transcriptional analyses of sarA sarS and agr sarS double mutants indicated that the agr locus likely downregulates spa transcription
by repressing sarS expression, whereas the sarA locus probably

Staphylococcus aureus is a versatile human pathogen that can
cause a variety of infections ranging from minor wound infections, pneumonia, and endocarditis to sepsis (3). The ability of
S. aureus to cause a multitude of diseases has been ascribed to
the array of extracellular and cell wall virulence determinants
produced by this microorganism (27). The regulation of many
of these virulence determinants is controlled by global regulatory loci such as sarA (previously designated as sar), agr, sae,
and rot (8, 13–16, 23). These regulatory elements, in turn, exert
transcriptional control of target virulence genes.
The global regulatory locus agr encodes a two-component
quorum-sensing system that originates from the generation of
two divergent transcripts, RNAII and RNAIII. RNAIII is the
effector molecule of the agr response, which entails upregulation of extracellular protein production (e.g., alpha-toxin)
and downregulation of cell wall-associated protein synthesis
(e.g., protein A and fibronectin-binding proteins) during the
postexponential phase (16). The RNAII transcript encodes
a four-gene operon, agrBDCA, with AgrC and AgrA corresponding to the sensor and the activator proteins of a twocomponent regulatory system (16). Additionally, AgrD encodes a 46-residue peptide which undergoes processing to
form a quorum-sensing cyclic octapeptide, probably with the
aid of the agrB gene product. Upon extracellular accumulation
of a critical concentration of the cyclic octapeptide, the sensor
protein AgrC will become phosphorylated (19), thus leading to
a second phosphorylation step of AgrA. Phosphorylated AgrA
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TABLE 1. Strains and plasmids used in this study
Strain or
plasmid

S. aureus
RN4220
RN6390
RN6911
PC1839
ALC184
ALC865
ALC1016
ALC1342
ALC1794
ALC1927
ALC2009
ALC2033
ALC2034
ALC2057
ALC2067
ALC2115

Source or
reference

25
25
26
4
7
7
This
This
9
This
This
This
This
This
This
This

study
study
study
study
study
study
study
study
study

Comments

A mutant of 8325-4 that accepts foreign DNA
Laboratory strain that maintains its hemolytic pattern when propagated on sheep erythrocyte agar
(parental strain)
An agr mutant of RN6390 with a ⌬agr::tetM mutation
8325-4 with a sarA::kan mutation
sarA mutant of RN6390 with pRN6735 and pI524
RN6911 (agr mutant) with pALC862
RN6390 with pALC1014
A sarA mutant in which the sarA gene (nt 586 to 1107) (1) has been replaced by an ermC gene
RN6390 with pALC1639
A sarS mutant of RN6390 with an ermC gene into the EcoRI site of the sarS gene
ALC1927 complemented with pALC2010
RN6390 with ⌬agr::tetM and sarS::ermC mutations
ALC1927 (sarS mutant) with pALC1639
RN6390 with a sarA::kan mutation
RN6390 with sarS::ermC and sarA::kan mutations
ALC1927 (sarS mutant) with pALC1014

E. coli
XL1-Blue
BL21

21
21

A host strain for cloning
A host strain for the pET14b expression vector

Plasmids
pCR2.1
pUC18
pCL52.2
pET14b
pI524
pLC4
pRN6735

Invitrogen
21
17
Novagen
16
31
16

E. coli cloning vector for direct cloning of PCR products
E. coli cloning vector
A temperature-sensitive E. coli-S. aureus shuttle vector
Expression vector for E. coli
S. aureus plasmid containing a ␤-lactamase repressor
A shuttle plasmid containing a promoterless xylE reporter gene
A derivative of pC194 containing the bla promoter and two-thirds of the blaZ gene followed by a
1.5-kb RNAIII fragment lacking its promoter
A shuttle vector containing pUC19 at the HindIII site of pC194
pCR2.1 with a 161-bp sarA P3 promoter fragment
pSK236 containing the entire sarA locus with the sarA ORF and the triple promoter system
pLC4 containing a 158-bp spa promoter fragment (nt 17 to 174) (20)
pLC4 (transcriptional fusion vector) with a 491-bp spa promoter fragment (nt 1 to 174 plus 319 bp
upstream) (20)
pUC18 containing a 1.8-kb sarS fragment (nt 2925 to 1082 in contig 6207)
Temperature-sensitive shuttle plasmid pCL52.2 containing the ermC gene at the EcoRI site (nt
2616 to 2621) of the 1.8-kb sarS fragment
Shuttle plasmid pSK236 containing a 1.2-kb sarS fragment (nt 3459 to 2189 of contig 6207)
pCR2.1 with a 1,562-bp spa structural gene (nt 219 to 1780) (20).
pET14b containing the 750-bp sarS gene at the XhoI/BamHI site

pSK236
pALC672
pALC862
pALC1014
pALC1639

12
This study
7
This study
9

pALC1883
pALC1889

This study
This study

pALC2010
pALC2040
pALC2043

This study
This study
This study

suppresses protein A expression via a different mechanism. Gel
shift analysis revealed that purified SarS binds to the spa promoter in a dose-dependent fashion. In contrast to the suppressive effect of sarA and agr, these data suggested that sarS
activates protein A synthesis. The fact that sarS is repressible
by agr and not vice versa hints at the possibility that agr may
exert its effect on spa by repressing sarS expression.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth media. The bacterial strains and
plasmids used in this study are listed in Table 1. CYGP, O3GL media (25), and
tryptic soy broth were used for the growth of S. aureus strains, while LuriaBertani medium was used to cultivate Escherichia coli. Antibiotics were used at
the following concentrations: erythromycin at 5 g/ml, kanamycin at 75 g/ml,
tetracycline at 5 g/ml, and ampicillin at 50 g/ml.
Genetic manipulations in E. coli and S. aureus. Based on homology with sarA,
the sarS gene was identified in contig 6207 in the TIGR S. aureus genome
database (www.TIGR.org). To construct a sarS mutant, part of the sarS gene,
together with a part of flanking sequence, was amplified by PCR with the
primers 5⬘-AGTTTTATGTTATAAACAATCGGA-3⬘ and 5⬘-GTTGTTTCTT
GTTATTTTACGAA-3⬘, using chromosomal DNA from strain RN6390 as the
template. The 1.8-kb PCR fragment (nucleotides [nt] 2925 to 1082 in contig

6207) was cloned into pUC18 in E. coli. Taking advantage of an internal EcoRI
site (nt 2616 to 2621) in the middle of the sarS coding region (nt 3098 to 2346),
we cloned a ⬃1.4-kb ermC fragment into this site. The fragment containing an
ermC insertion into the sarS gene was cloned into the temperature-sensitive
shuttle vector pCL52.2 (18), which was then transformed into RN4220 by electroporation (28), followed by transduction into RN6390 with phage 11 as
described elsewhere (8). Transductants were selected at 30°C on erythromycinand tetracycline-containing plates.
S. aureus RN6390 harboring the recombinant pCL52.2 was grown overnight at
30°C in liquid medium in the presence of erythromycin, diluted 1:1,000 in fresh
media, and propagated at 42°C, a nonpermissive temperature for the replication
of pCL52.2. This cycle was repeated four times, and the cells were replicate
plated onto O3GL plates containing erythromycin and erythromycin-tetracycline
to select for tetracycline-sensitive but erythromycin-resistant colonies, representing mutants with double-crossovers. The mutations were confirmed by Southern
hybridization with sarS and ermC probes. One clone, designated ALC1927, was
selected for further study.
To complement the sarS mutation in ALC1927, we introduced a 1.2-kb PCR
fragment (nt 2925 to 1082 in contig 6207) encompassing the sarS gene into the
shuttle plasmid pSK236. The recombinant shuttle plasmid was first electroporated into RN4220 and then into the sarS mutant ALC1927 (8). The presence of
the recombinant plasmid was confirmed by restriction mapping. The presence of
the sarS transcript in the complemented mutant was confirmed by Northern blots
with a sarS probe.
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For the construction of the sarA sarS double mutant, we introduced the
sarA::kan mutation into sarS mutant ALC1927 via a 80␣ lysate of a sarA insertion
mutant PC1839 (with a sarA::kan mutation). As an additional control, we used a
sarA deletion mutant (ALC1342) in which the sarA gene has been replaced by
the ermC gene. Because of the ermC insertion, we were not able to construct a
sarA sarS mutation in the ALC1342 background. Likewise, an agr sarS mutant
was constructed by infecting the sarS mutant with a 11 lysate of the agr mutant
RN6911. The authenticity of these double mutants was confirmed by Southern
and Northern blots with sarA and agr probes (data not shown).
Analysis of hla and spa expression in the sarS mutant and its isogenic parents.
To assess the phenotypes of the sarS mutant, we first evaluated the expression of
␣ hemolysin and protein A, two well-known virulence determinants in S. aureus.
To determine ␣-hemolysin expression, equivalent amounts of extracellular proteins that had been harvested at stationary phase and concentrated by 10%
trichloroacetic acid precipitation were blotted onto nitrocellulose, probed with
rabbit anti-␣-hemolysin antibody (a gift from B. Menzies, Nashville, Tenn.) diluted 1:2,000, and then treated with the F(ab)2 fragment of goat anti-rabbit alkaline phosphatase conjugate (Jackson Immunoresearch, West Grove, Pa.) as
described previously (5). Reactive bands were visualized as described by Blake
et al. (2).
To evaluate protein A production, cell wall-associated proteins were extracted
from an equivalent number of S. aureus cells (from overnight cultures) with
lysostaphin in a hypertonic medium (30% raffinose) to stabilize the protoplasts as
described previously (7). Equivalent volumes (1 to 2 l each) of cell wall protein
extracts from 25 ml of cells (109 CFU/ml) were resolved on 10% sodium dodecyl
sulfate-polyacrylamide gels, blotted onto nitrocellulose, and probed with chicken
anti-staphylococcal protein A antibody (Accurate Chemicals, Westbury, N.Y.) at
a 1:3,000 dilution. Bound antibody was detected with a 1:5,000 dilution of F(ab)2
fragment of rabbit anti-chicken immunoglobulin G conjugated to alkaline phosphatase (Jackson Immunoresearch), followed by the addition of developing
substrates (2). The intensity of the protein A band was quantitated by densitometric software (SigmaGel; Jandel Scientific). The data are presented as densitometric units.
Isolation of RNA and Northern blot hybridization. Overnight cultures of S.
aureus were diluted 1:50 in CYGP and grown to mid-log (optical density at 650
nm [OD650] ⫽ 0.7), late-log (OD650 ⫽ 1.1), and early-postexponential (OD650 ⫽
1.7) phases. The cells were pelleted and processed with a FastRNA isolation kit
(Bio 101, Vista, Calif.) in combination with 0.1-mm-diameter zirconia-silica
beads in a FastPrep reciprocating shaker (Bio 101) as described earlier (6). Ten
or twenty micrograms of each sample was electrophoresed through a 1.5%
agarose–0.66 M formaldehyde gel in morpholinepropanesulfonic acid (MOPS)
running buffer (20 mM MOPS, 10 mM sodium acetate, 2 mM EDTA; pH 7.0).
Blotting of RNA onto Hybond N⫹ membranes (Amersham, Arlington Heights,
Ill.) was performed with the Turboblotter alkaline transfer system (Schleicher &
Schuell, Keene, N.H.). For the detection of specific transcripts (agr, sarA, sarS,
spa, and hla), gel-purified DNA probes were radiolabeled with [␣-32P]dCTP by
the random-primed method (Ready-To-Go Labeling Kit; Pharmacia) and hybridized under high-stringency conditions (5). The blots were subsequently
washed and autoradiographed.
Preparation of cell extracts for detection of SarA. Cell extracts were prepared
for strains RN6390 and the corresponding sarS mutant. After pelleting, the cells
were resuspended in 1 ml of TEG buffer (25 mM Tris, 5 mM EGTA; pH 8), and
cell extracts were prepared from lysostaphin-treated cells as described earlier
(11). Cell extracts were immunoblotted onto nitrocellulose membranes as described above. For the detection of SarA, monoclonal antibody 1D1 (1:2,500
dilution) was incubated with the immunoblot for 3 h, followed by another h of
incubation with a 1:10,000 dilution of goat anti-mouse alkaline phosphatase
conjugate (Jackson Immunoresearch). Reactive bands were detected by developing substrates as described previously (2).
Transcriptional fusion studies of spa promoter linked to the xylE reporter
gene. A 158-bp (nt 17 to 174) (20) and a 491-bp spa promoter fragment (9) with
flanking EcoRI and HindIII sites were amplified by PCR using genomic DNA of
S. aureus RN6390 as the template and cloned into the TA cloning vector pCR2.1
(Invitrogen, San Diego, Calif.). The EcoRI-HindIII fragments containing the spa
promoter were then cloned into shuttle plasmid pLC4 (31), generating transcriptional fusions to the xylE reporter gene. The orientation and authenticity of the
promoter fragments were confirmed by restriction analysis and DNA sequencing.
The recombinant plasmids were first introduced into S. aureus RN4220 by electroporation, according to the protocol of Schenk and Laddaga (28). Plasmids
purified from RN4220 transformants were then electroporated into RN6390 and
its isogenic sarS mutant.
For enzymatic assays of the xylE gene product, overnight cultures were diluted
1:50 or 1:100 in 250 ml of TSB containing appropriate antibiotics and shaken
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at 37°C and 200 rpm. Starting after 3 h of growth, 10 to 50 ml of cell culture
corresponding to different OD600 values was serially removed, centrifuged, and
washed twice with 1 ml of ice-cold 20 mM potassium phosphate buffer (pH 7.2).
The pellets were resuspended in 500 l of 100 mM potassium phosphate buffer
(pH 8.0) containing 10% acetone and 25 g of lysostaphin per ml, incubated for
15 min at 37°C, and then kept on ice for 5 min. Extracts were centrifuged at
20,000 ⫻ g for 50 min at 4°C to pellet cellular debris. The XylE (catechol
2,3-dioxygenase) assays were determined spectrophotometrically at 30°C in a
total volume of 3 ml of 100 mM potassium phosphate buffer (pH 8.0) containing
100 l of cell extract and 0.2 mM catechol as described earlier (31). The reactions
were allowed to proceed for 25 min with an OD375 reading taken at the 25-min
time point. One milliunit is equivalent to the formation of 1.0 nmol of 2-hydroxymuconic semialdehyde per min at 30°C. The specific activity is defined as a
milliunit per milligram of cellular protein (31).
Overexpression and purification of SarS in a pET vector. The 750-bp sarS
gene was amplified by PCR using the following oligonucleotides: 5⬘-GCCG(CT
CGAG)ATGAAATATAATAACCA-3⬘ and 5⬘-GCACTTTA(GGATCC)AGC
ACAC-3⬘. The PCR product was digested with XhoI and BamHI (restriction
sites are indicated in parentheses), ligated into the expression vector pET14b
(Novagen, Madison, Wis.), and transformed into the E. coli BL21(DE3).pLys.S.
The resulting plasmid (pALC2043; see Table 1) contained the entire sarS coding
region in frame with a N-terminal His tag. Recombinant protein expression was
induced by adding ITPG (isopropyl-␤-D-thiogalactopyranoside; final concentration, 1 mM) to a growing culture (30°C) at OD600 of 0.5. At 3 h after induction,
the cells were harvested, resuspended in binding buffer (5 mM imidazole, 0.5 M
NaCl, 20 mM Tris-HCl; pH 7.9), and sonicated on ice. Cellular debris was
removed by centrifugation at 15,000 ⫻ g for 15 min, and the clarified supernatant
was purified on a nickel affinity column (Novagen) according to the manufacturer’s instructions. The protein was eluted with the elution buffer (1 M imidazole, 0.5 M NaCl, 20 mM Tris-HCl; pH 7.9), followed by dialysis in the same
buffer lacking the imidazole. The authenticity of the purified SarS protein was
confirmed by N-terminal sequencing, and the size of the recombinant protein was
verified by sodium dodecyl sulfate-gels stained with Coomassie blue.
Gel shift assays. To determine if the recombinant SarS protein binds to the spa
promoter, DNA fragment (158 bp) was end labeled with [␥-32P]ATP by using T4
polynucleotide kinase. Labeled fragments were incubated at room temperature
for 15 min with the indicated amount of purified protein in 25 l of binding
buffer (25 mM Tris-HCl, pH 7.5; 0.1 mM EDTA; 75 mM NaCl; 1 mM dithiothreitol; 10% glycerol) containing 0.5 g of calf thymus DNA. The reaction
mixtures were analyzed by nondenaturing polyacrylamide gel electrophoresis.
The band shifts were detected by exposing dried gels to film.

RESULTS
Identification of the sarS gene. Predicated upon the SarA
protein sequence, we ran the BlastP program against the TIGR
S. aureus genomic database. One of the matches is located upstream of the spa gene (contig 6207, with the coding region
from nt 3098 to 2349). An identical gene, designated sarS, was
also found in contig 773 at the University of Oklahoma genome database. This gene, preceded by a typical Shine-Dalgarno sequence (AGGAGA) located 7 bp upstream of the
initiation codon, contains a 750-bp ORF encoding a 29.9-kDa
protein with a deduced pI of 9.36. A putative transcription
terminal signal corresponding to a 13-bp inverted repeats (nt
2345 to 2301 in contig 6207) is located 10 bp downstream of the
TAA stop codon. About 33.2% of the residues are charged.
Like that of SarA, the relatively small size, a predominance of
charged residues, and a basic pI of SarS are features consistent
with regulatory proteins in prokaryotes (29). An alignment of
SarS with SarA revealed that SarS has two regions of identity
with SarA, with the first region (residues 1 to 125) having
28.3% identity and the second region having 34.5% identity
(Fig. 1). The extent of homology is relatively global in nature.
A survey of the GenBank database indicated that SarS is identical to the SarHI homolog recently reported by Tegmark et al.
(30). Interestingly, SarS is also homologous to SarR (22), a

VOL. 69, 2001

CHARACTERIZATION OF sarS IN S. AUREUS

2451

FIG. 1. Sequence alignment of SarS, SarA, and SarR. SarS is 250 residues long. Based on regional homology, SarS can be divided into two
domains (S1 and S2) of 125 residues each. The homology with SarA is higher with the C-terminal domain (34.5%) than with the N-terminal domain
(28.3%). The consensus residues are in black boxes. The consensus residue, designated as the majority at each position, is assigned when at least
half of the residues have the same amino acid.

recently described SarA homolog that downregulates SarA
protein expression.
Expression of sarS in RN6390 and its isogenic sarA and agr
mutants. To assess the role of sarS within the sarA/agr regulatory cascade and its mode of control on virulence gene expression, we proceeded to construct a sarS mutant by inserting an
ermC gene into the EcoRI site within the sarS gene in strain
RN6390 (see Materials and Methods), thus resulting in a truncation of 91 residues from the C terminus. PCR with an ermC
(5⬘-ATGGTCTATTTCAATGGCAGTTAC) primer and a
sarS primer (5⬘-AGGCTTTGGATGAAGCCGTTAC) outside
the construct yielded a fragment consistent with the insertion
of ermC into the sarS gene. Subsequent sequencing of the PCR
product has verified the disruption of the sarS gene in the
mutant. This was also corroborated with Southern blots with
selected ermC and sarS probes (data not shown).
A Northern blot with a sarS probe (nt 3098 to 2349 in contig
6207), encompassing only the sarS coding region, revealed that
the sarS gene is poorly transcribed in the parental strain
RN6390, thus rendering the absence of the sarS gene difficult
to decipher in the sarS mutant. Interestingly, the transcription
of the sarS gene, sizing at 930 nt, was more prominent in both
agr and sarA mutants of RN6390 (Fig. 2A). In particular, in the
sarA mutant, the sarS transcript was detected at late exponential phase (OD650 ⫽ 1.1 using an 18-mm borosilicate glass
tube) and was maximally transcribed during the postexponential phase (OD650 ⫽ 1.7). The transcription of sarS was also
increased in the agr mutant, but the magnitude of the increase
was less than that of the sarA mutant (Fig. 2A). In contrast to
the sarA mutant, the agr mutant expressed the sarS transcript
maximally during the late exponential phase. To assess the
relative contributions of sarA and agr to sarS repression, we

assayed the sarS transcript level in an agr mutant complemented with a plasmid carrying the entire sarA locus (5), as
well as in a sarA mutant complemented with a fragment encoding RNAIII, the agr regulatory molecule. Remarkably, the
transcription of sarS, augmented in an agr mutant, was repressed in the agr mutant clone expressing sarA in trans (Fig.
2B). However, we were not able to detect transcriptional repression of sarS in a sarA mutant expressing RNAIII of agr,
thus implying a differential role for sarA and agr in repressing
sarS transcription.
We also examined the transcription of sarA and agr loci in
the sarS mutant. Northern analysis of RNAII and RNAIII did
not reveal any differences between the parental strain and the
isogenic sarS mutant (data not shown). Likewise, the expression of three sarA transcripts (designated sarA P1, P3, and P2
transcripts) was similar between the two isogenic strains. Since
SarA is encoded by these transcripts (1), we also probed for
SarA expression in an immunoblot of the cell extracts of the
isogenic pair (25 g of protein in each lane) with 1D1 antiSarA monoclonal antibody (10). Our data showed that the
expression of SarA was comparable between RN6390 and its
isogenic sarS mutant (data not shown). Collectively, these data
implied that the transcription of sarS is repressed by the sarA
and agr gene products and not vice versa.
Assessment of hla and spa in a sarS mutant of S. aureus.
Cognizant of the fact that both ␣-hemolysin and protein A are
regulated by sarA and agr, two regulatory loci capable of repressing sarS expression, we proceeded to evaluate hla and spa
expression in the sarS mutant. In an immunoblot in which
equivalent amounts of extracellular proteins were blotted onto
nitrocellulose and probed with rabbit anti-␣-hemolysin antibody (1:2,500 dilution), we found that ␣-hemolysin was syn-
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FIG. 2. (A) Northern blot of the sarS transcripts in sarA, agr, sarA
sarS, and agr sarS mutants. A total of 20 g of cellular RNA was loaded
onto each lane. The intensity of the 16S and 23S RNA band was found
to be equivalent among lanes prior to transfer to Hybond N⫹ membrane. The blot was probed with a 750-bp sarS fragment (nt 2349 to
3098 in contig 6207) labeled with [␣-32P]dCTP, washed, and autoradiographed. Both sarA and sarA sarS mutants contained the sarA::kan
mutation. The sarA deletion mutant ALC1342 in which the sarA gene
has been replaced by an ermC gene was used as an additional control.
(B) Northern blot of the sarS transcript in sarA mutant (ALC136) and
agr mutant with agr and sarA provided in trans, respectively. The sarA
mutant was complemented with pRN6735, yielding ALC184. The plasmid pRN6735 was basally transcribed, yielding a low level of RNAIII
transcript (data not shown) even in the presence of a repressor plasmid
pI524. The agr mutant RN6911 was complemented with pALC862, a
recombinant pSK236 containing the entire sarA locus.

thesized in the sarS mutant at a level similar to that of the
parental strain. Northern blotting with an hla probe also confirmed comparable levels of gene expression between the two
strains (data not shown).
To ascertain the effect of a sarS mutation on spa expression,
we first assayed for transcriptional activity of 491-bp (9) and
158-bp (20) spa promoter fragments linked to the xylE reporter
gene in the isogenic sarS strains. Based on XylE assays, the
activity of the 491-bp spa promoter fragment was lower in the
sarS mutant (29.6 ⫾ 0.06 and 24.0 ⫾ 0.28 mU /mg of cellular
proteins at OD650 values of 1.1 and 1.7, respectively) than in its
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isogenic parent (53.4 ⫾ 0.06 and 74 ⫾ 1.3 MU/mg of cellular
proteins for OD650 values of 1.1 and 1.7, respectively). A similar expression pattern was also observed with the 158-bp spa
promoter fragment, but the magnitude of the XylE activity was
much less in both isogenic strains (data not shown). We next
probed an immunoblot, containing equivalent amounts of cell
wall protein extracts of the mutant and complemented mutant,
with affinity-purified chicken anti-protein A antibody (1:3,000
dilution). As displayed in Fig. 3, the expression of protein A
was higher in the parental strain than in the sarS mutant.
However, upon complementation with a plasmid expressing
the sarS gene, the expression of protein A was increased to
near parental level. These data implicated sarS to be involved
in the upregulation of spa expression in S. aureus.
Analysis of spa transcription in agr, sarA, agr sarS, and sarA
sarS mutants. Since both sarA and agr repress sarS (see above)
and spa transcription (7), we wanted to assess the relative
contribution of sarS, as mediated by sarA and agr, in spa repression. For this purpose, we compared spa transcription of
the sarA sarS and agr sarS double mutants to single sarA and
agr mutants in the RN6390 background. In a previous study of
the effect of agr and sarA on spa transcription (7), we chose
strain RN6390 since this strain has a low basal level of spa
transcription that can be accentuated by selective mutations.
As shown in Fig. 4A, the transcription of spa, while enhanced
in an agr mutant, was significantly reduced in the agr sarS
double mutant, thus demonstrating that agr likely mediates spa
repression by downregulating sarS. On the contrary, the upregulation in spa expression in a sarA mutant (sarA::kan) was
maintained in the sarS-sarA::kan double mutant. As an additional control, the sarA deletion mutant ALC1342 also expressed a high level of spa transcription. A similar expression
pattern was also observed in an immunoblot of cell wall protein
A for these strains (Fig. 4B), demonstrating repression in pro-

FIG. 3. Immunoblot of equivalent amounts of cell wall extracts
of RN6390, sarS mutant, and complemented mutant. The blot was
probed with affinity-purified chicken anti-protein A antibody at a
1:3,000 dilution, followed by the addition of the appropriate conjugate
and substrate. The portion of the blot labeled “5X” represents five
times as much cell wall extracts as the lanes labeled as “1X.” Purified
protein A (0.1 g) was used as a positive control.
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FIG. 4. (A) Northern blot of the spa transcript in agr, sarA, sarS agr,
and sarS sarA mutants. The sarA and the sarS sarA mutants had the
sarA::kan mutation. A total of 10 g of RNA was applied to each lane.
The blot was probed with a 1,562-bp spa fragment (nt 219 to 1780)
(20). The parental strain RN6390 was a low protein A producer, with
a very reduced level of spa transcription (7). The sarA deletion mutant
ALC1342 served as a positive control. (B) Immunoblot of cell wall
extracts of agr, sarA, sarS agr, and sarS sarA mutants probed with
chicken anti-protein A antibody. Equivalent amount of cell wall extracts was applied to each lane. The positive control is purified protein
A (0.1 g). The big arrow points to intact protein A, while the two
smaller arrows highlight degraded protein A fragments in the sarA::
kan mutant (ALC2057).

tein A expression in the agr sarS mutant (175 densitometric
units) compared with the single agr mutant (264 densitometric
units). However, the contribution of sarS to the sarA mutant
(i.e., the sarA sarS double mutant) was more difficult to decipher since there were two major protein A bands of lower
molecular size in the sarA mutant (corresponding to densitometric units of 314 and 131 for the upper and lower bands,
respectively) compared with the sarS sarA double mutant (346
densitometric units). The lower protein A bands may have
been attributable to enhanced proteolytic activity in the sarA
mutant, as has been previously reported (4, 8). Nevertheless, in
comparing the intensity of the protein A band between the
double sarS sarA mutant (346 densitometric U) and the agr
mutant (264 densitometric U), we surmised that the expression
of protein A in the double mutant was not significantly lower
than in the single sarA mutant (two bands at 314 and 131

CHARACTERIZATION OF sarS IN S. AUREUS

2453

densitometric U). Unlike the single sarA mutant, the sarS sarA
double mutant did not exhibit a protein A band of smaller
molecular size. Whether sarS plays a role in modulating proteolytic activity in the sarA mutant remains to be determined.
Nevertheless, these data collectively supported the notion that
the agr locus, in distinction to the sarA locus, likely mediates
spa repression via a sarS-dependent pathway.
To corroborate the view that agr and sarA mediate spa repression via different pathways, we determined spa transcription in an agr mutant complemented with a shuttle plasmid
carrying the entire sarA locus in trans, as well as in a sarA
mutant with a plasmid expressing RNAIII. Although this approach represented a higher gene dosage than at the physiologic level, the result of this experiment, coupled with those of
sarS expression, provide additional evidence for the regulatory
linkage between agr and spa, using SarS as an intermediary.
Accordingly, the transcription of spa in an agr mutant with sarA
provided in trans (Fig. 5), as with the expression of sarS (Fig.
2B), was repressed compared to the agr mutant control. In
contrast, a sarA mutant with agr expressed in trans, while maintaining an elevated level of sarS transcription compared with
the parent (Fig. 2B), was still able to repress spa transcription
(Fig. 5). Taken together, our results clearly indicated that sarA
and agr repress spa transcription via divergent pathways, with
agr being dependent on sarS, while the effect of sarA on spa is
sarS independent.
Gel shift assay of SarS with the spa promoter fragment.
Recognizing that the sarS gene product may be an activator of
protein A synthesis, we proceeded to evaluate the binding of
the SarS protein to the spa promoter. For this experiment, we
cloned the sarS gene into the pET14b expression vector (Novagen, Madison, Wis.) in E. coli BL21. SarS was then overexpressed in inducing conditions with 1 mM IPTG and purified
with a nickel affinity column from the crude cell lysate according to the manufacturer’s instructions. SarS, as eluted from the
column, was essentially homogeneous (⬎95%) (Fig. 6A). Using purified SarS protein, we conducted gel shift assays of SarS
with a 158-bp spa promoter fragment (nt 17 to 174) (20). As

FIG. 5. Northern blot of the spa transcript in sarA and agr mutants,
with agr and sarA provided in trans, respectively. The strains used in
this blot are identical to those in Fig. 2B. The positive control is a plasmid (pCR2.1) carrying a 1,562-bp spa fragment (nt 219 to 1780) (20).
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FIG. 6. (A) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of SarS purified from the pET14b expression vector. About 5
g of purified SarS protein was applied to the lane. The gel was stained
with Coomassie blue. (B) Gel shift assay of purified SarS with a 158-bp
spa promoter fragment (nt 17 to 174) (20). The spa promoter fragment
was end labeled with [␥-32P]ATP. About 25,000 cpm was used in each
lane. Increasing concentrations of purified SarS (0.125, 0.25, 0.5, 1, and
2 g of SarS) were used in the lanes. The specific competitor was the
cold unlabeled 158-bp spa promoter. The nonspecific competitor was a
161-bp sarA P3 promoter fragment (nt 365 to 525) (1).

displayed in Fig. 6B, SarS was able to retard the mobility of the
spa promoter fragment in a dose-dependent fashion. Notably,
the laddering pattern in the gel shift assay is consistent with
either multimers of SarS binding to the spa promoter or multiple binding sites on the spa promoter or both. In competition
assays with unlabeled spa promoter fragment, the gel retarding
activity of SarS was abolished, thus demonstrating the specificity of the binding.
DISCUSSION
In prior studies with sarA and agr in S. aureus, it was observed that both of these regulatory loci play important roles in
repressing spa transcription during the postexponential phase.
Thus, the synthesis of protein A occurs primarily during the
exponential phase and is repressed postexponentially. Predicated upon this observation, it seems reasonable to hypothesize that an activator of protein A synthesis likely exists within
the staphylococcal genome. In searching the partially released
genome for homologs of SarA, the major sarA regulatory mol-
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ecule, we found an ORF encoding a SarA homolog (SarS)
upstream of spa. In contrast to SarA (124 residues), the longer
SarS protein (250 residues) can be divided into two SarAhomologous domains of 125 residues each. The C-terminal
domain of SarS appears to share a high degree of similarity
with SarA (34.5 identity versus 28.3% for the N-terminal domain). The SarS protein, like SarA, has a basic pI and a high
percentage of charged residues (33.2 versus 33% for SarA),
features consistent with DNA-binding proteins in prokaryotes.
Indeed, gel shift studies of purified SarS with a 158-bp spa
promoter fragment supported the notion that SarS is likely a
DNA-binding protein, modulating the transcription of the spa
gene.
In searching the literature, we found that SarS is identical to
SarH1 recently reported by Tegmark et al. (30). Using a fragment encompassing only the 750-bp sarS coding region as a
probe, we were only able to detect a single 930-nt sarS transcript as opposed to the three transcriptional units (1.0, 1.5,
and 2.9 kb) described in those earlier studies. This transcript
likely corresponds to the most prominent transcript reported
by Tegmark et al. (30). It is not immediately apparent why such
differences in transcription exist between our studies and
theirs. We surmise that the hybridization (65°C) and washing
(60°C with 0.1⫻ SSC [1⫻ SSC is 0.15 M NaCl plus 0.015 M
sodium citrate]) conditions in our Northern blot studies might
be more stringent. It is also plausible that the larger but weaker
bands in their study may be cross-hybridizing bands. Alternatively, the smaller 1.5-kb band may be a processed product
from the larger 2.9-kb transcript. In any event, in the absence
of additional primer extension data (for the 2.9-kb transcript)
and transcriptional fusion studies of the putative promoters for
the 1.5- and 2.9-kb transcripts, it is not certain if other promoters are part of the sarS operon.
Despite differences in sarS transcriptional patterns between
the two studies, we confirmed that sarS is repressed by sarA
and agr. However, the mode of sarS repression, as revealed by
our data, differed between the two global regulatory loci. More
specifically, inactivation of sarA yielded a higher level of sarS
expression on Northern blots than that of the agr mutant (Fig.
2A). Additional Northern blot studies divulged that the elevated sarS level in an agr mutant can be repressed by a plasmid
supplying sarA in trans. In contrast, the sarS level remained
high in a sarA mutant even when a plasmid encoding RNAIII
was present. More importantly, despite a dissimilarity in the
sarS level, spa transcription was repressed in the agr mutant
with sarA supplied in trans as well as in the sarA mutant expressing RNAIII from a plasmid source. Although the gene
dosage (i.e., sarA or RNAIII) in these studies is not provided
at the single-copy level, we contend that the expression of sarA
or agr from multiple-copy plasmid would still permit us to
decipher the putative interactive pathway, in particular in a
situation where the putative gene (e.g., sarS) is expressed at
such a low level that it may easily be missed by routine Northern blot analysis. Thus, a persistently high sarS level in the sarA
mutant expressing RNAIII in trans (Fig. 2B), coupled with an
effective repression of spa (Fig. 5), hinted at the differential
roles in spa regulation between sarA and agr.
Several lines of experimental evidence suggested a role for
sarS as an activator of protein A synthesis. First, in complementation studies of the sarS mutant, we showed by immuno-
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blots that the diminution in protein A synthesis was restored by
a shuttle plasmid carrying sarS. Second, we confirmed by transcriptional fusion studies of a spa promoter linked to the xylE
reporter gene that spa promoter activity was indeed reduced in
a sarS mutant. Third, gel shift studies have validated the notion that SarS can bind directly to the spa promoter in a dosedependent fashion. Fourth, we extended our observation by
Northern analyses that the upregulation in spa transcription in
an agr mutant, presumably mediated by a derepression of sarS,
was abolished in an agr sarS double mutant, thus implicating
the role of sarS in activating spa transcription in an agr mutant.
However, contrary to the data of Tegmark et al., we found that
spa transcription in a sarA sarS double mutant, as with a single
sarA mutant, remained elevated. Thus, despite the experimental observation that sarS is derepressed in a sarA mutant, the
continued augmentation in spa transcription in a sarA sarS
double mutant implied that the sarA locus likely represses
protein A synthesis via a SarS-independent pathway. In this
regard, our recent finding that SarA, the major sarA regulatory
molecule, can directly bind to a consensus recognition sequence upstream of spa promoter to downregulate spa transcription would provide an explanation for an alternative
mechanism for direct SarA-mediated spa repression (9). Alternatively, other intermediate factor(s) controlled by sarA or
other factors that act in conjunction with SarS may play a role
in sarA-mediated spa repression. It is also plausible that these
“controlling factors” may be mediated via agr, since RNAIII
supplied in trans in a significant gene dosage in a sarA mutant
could also suppress spa transcription (Fig. 5). Nonetheless, we
are left to offer an explanation for the high level of sarS expression in a sarA mutant. Perhaps, it may be reasonable to
interpret the upregulation in sarS in terms of hla repression,
since Tegmark et al. found that a sarA sarH1 (i.e., sarA sarS)
mutant, as opposed to a single sarA mutant, exhibited an upregulation in hla transcription.
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